List of Excipients in Branded Drug LITHOSTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	LITHOSTAT	acetohydroxamic acid	0178-0500	CELLULOSE, MICROCRYSTALLINE
Mission Pharmacal Company	LITHOSTAT	acetohydroxamic acid	0178-0500	MAGNESIUM STEARATE
Mission Pharmacal Company	LITHOSTAT	acetohydroxamic acid	0178-0500	PEPPERMINT OIL
Mission Pharmacal Company	LITHOSTAT	acetohydroxamic acid	0178-0500	SILICON DIOXIDE

LITHOSTAT Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

LITHOSTAT is an oral acetohydroxamic acid tablet used with antibacterial therapy to inhibit bacterial urease in patients with chronic infection-related urinary stones. Its commercial opportunity is driven less by new chemical-entity exclusivity and more by formulation performance, supply reliability, patient tolerability, and regulatory execution. The strongest product concepts are differentiated immediate-release tablets, lower-burden presentations, and patient-friendly dosage forms supported by a 505(b)(2) or generic development strategy.

What is LITHOSTAT and how does it work?

LITHOSTAT contains acetohydroxamic acid, a urease inhibitor. Urease-producing organisms hydrolyze urea and increase urinary ammonia and pH, promoting formation of infection-related stones, including struvite and carbonate apatite stones. Acetohydroxamic acid inhibits this enzymatic pathway and is used as an adjunct to antibacterial therapy and surgical management where appropriate.

The product is not an antibiotic and does not eradicate the underlying infection. Its commercial positioning is therefore tied to a narrow urology population with recurrent or persistent infection-related stone disease.

Attribute	LITHOSTAT
Active ingredient	Acetohydroxamic acid
Dosage form	Oral tablet
Common strength	250 mg
Therapeutic class	Urease inhibitor
Primary use	Adjunctive treatment of infection-related urinary stones
Reference product holder	Mission Pharmacal Company
FDA pathway	Prescription drug
Principal safety constraints	Renal impairment, anemia, thromboembolic risk, gastrointestinal effects
Administration issue	Repeated daily dosing and tolerability management

The approved labeling limits use in patients with significant renal impairment and describes laboratory monitoring requirements, including hematologic surveillance. Those restrictions affect formulation design because improving adherence cannot come at the expense of increasing systemic exposure or reducing dose flexibility. (U.S. Food and Drug Administration [FDA], n.d.-a)

What excipients are used in LITHOSTAT tablets?

The commercial tablet uses a conventional immediate-release solid oral formulation. Public product labeling identifies inactive ingredients used to support tablet compression, disintegration, lubrication, and manufacturing robustness. The excipient platform is not a major barrier to entry because the formulation is technically conventional and does not depend on a complex delivery system.

The relevant excipient functions are:

Formulation function	Likely formulation requirement
Dilution and compressibility	Microcrystalline cellulose or another compactable filler
Binding	Povidone or equivalent binder
Disintegration	Sodium starch glycolate, croscarmellose sodium, or equivalent
Lubrication	Magnesium stearate
Flow control	Colloidal silicon dioxide or equivalent
Stability	Low-moisture excipient system and protective packaging

The central excipient problem is not release technology. It is balancing tablet size, mechanical strength, disintegration, chemical stability, and gastrointestinal tolerability. Acetohydroxamic acid is administered repeatedly, so a formulation that increases tablet mass or worsens swallowing difficulty would reduce the value of any apparent manufacturing benefit.

What excipient strategy is most attractive for LITHOSTAT?

The highest-value strategy is a robust immediate-release tablet with a lower excipient burden and improved patient usability.

1. High drug-load immediate-release tablet

A 250 mg tablet already contains a substantial active load relative to a typical small-molecule tablet. A high-load formulation could reduce tablet dimensions by using:

• Direct-compression excipients with high compactability
• Silicified microcrystalline cellulose
• Coprocessed excipient systems
• Low-level superdisintegrants
• Optimized particle-size distribution
• Granulation only where needed for flow or content uniformity

A smaller tablet would support adherence, particularly for patients taking multiple medications for urinary infection, renal disease, or stone prevention.

The principal development risks are sticking, capping, poor flow, and slower disintegration if compression force is increased to reduce tablet size. These risks can be managed through particle engineering and compression-process controls rather than by introducing a complex dosage form.

2. Reduced gastrointestinal burden

The LITHOSTAT label describes gastrointestinal adverse reactions, including nausea and vomiting. Excipients cannot eliminate active-ingredient-related toxicity, but they can reduce formulation-related irritation and improve dose administration.

Potential approaches include:

• Lower-impact lubricants
• Reduced levels of highly hygroscopic excipients
• Faster disintegration without excessive tablet porosity
• Film coating to improve mouthfeel and swallowing
• Packaging that limits moisture uptake and degradation

A film-coated tablet may have the strongest commercial value if it improves swallowability without materially changing dissolution. The coating should remain immediate-release and avoid creating a food-effect or delayed-release profile that would complicate regulatory bridging.

3. Modified-release formulations

A sustained-release product could reduce peak-related intolerance and dosing frequency, but it carries meaningful development risk. Acetohydroxamic acid is used to inhibit urease activity over time, and a controlled-release profile could theoretically reduce dosing frequency. The product, however, has important safety limitations and is eliminated through the kidney. A modified-release dosage form could complicate exposure management in patients with impaired renal function.

A modified-release product would require:

• Comparative pharmacokinetic studies
• Demonstration of adequate urease-inhibitory exposure
• Assessment of accumulation in renal impairment
• Clinical justification for the changed exposure profile
• A stronger 505(b)(2) package than a conventional generic tablet

The commercial return may not justify the added regulatory and clinical burden unless the product materially improves adherence or tolerability.

What formulations are protected by LITHOSTAT patents?

The publicly available FDA labeling and Orange Book framework do not indicate that LITHOSTAT depends on a currently prominent formulation-patent estate. The commercial protection profile is therefore more consistent with an established product whose competitive barriers are regulatory, manufacturing, clinical familiarity, and market size rather than a dense portfolio of active formulation patents. (FDA, n.d.-b)

Potentially relevant intellectual-property categories include:

IP category	Commercial relevance
Composition-of-matter patents	Likely historical rather than a current barrier
Immediate-release tablet patents	Limited barrier if conventional formulation claims are expired or absent
Modified-release patents	Potential opportunity for a new product, subject to obviousness and enablement risks
Excipient-specific claims	Usually narrow and vulnerable to design-around
Method-of-use patents	Could cover urease inhibition in selected stone populations
Manufacturing patents	May protect particle engineering, granulation, or impurity control
Packaging patents	Possible but unlikely to create durable market exclusivity alone

A developer should not assume that a new excipient combination creates enforceable differentiation. A defensible formulation patent would need to claim a specific composition or process linked to an unexpected technical result, such as improved stability, dissolution, bioavailability, impurity control, or tolerability.

When does LITHOSTAT lose exclusivity?

LITHOSTAT is an established acetohydroxamic acid product. Its original small-molecule exclusivity and any early composition patents are historical matters. The relevant commercial question is whether current FDA-listed patents or regulatory exclusivities block an abbreviated application.

The Orange Book should be reviewed for:

• Current patent listings associated with the reference NDA
• Patent expiration dates
• Use codes
• Pediatric exclusivity
• Thirty-month-stay eligibility
• Whether the reference product is active, discontinued, or listed as not available

If no unexpired listed patents or regulatory exclusivities remain, a conventional ANDA pathway may be available for a therapeutically equivalent acetohydroxamic acid tablet. A new dosage form, strength, route, or formulation would more likely require a 505(b)(2) application.

What is the Orange Book status of LITHOSTAT?

LITHOSTAT is associated with acetohydroxamic acid and a reference prescription-drug application. Orange Book analysis should distinguish between:

1. The reference listed drug.
2. Any therapeutically equivalent generic products.
3. Patent listings tied to the reference application.
4. Marketing status and availability.
5. Whether a discontinued product remains eligible as a reference for an abbreviated application.

The absence of a current patent barrier does not guarantee immediate generic entry. An applicant still must establish pharmaceutical equivalence, bioequivalence, manufacturing compliance, stability, labeling conformity, and commercial supply.

FDA’s Orange Book is the controlling public source for listed patents, exclusivity, therapeutic-equivalence codes, and reference-product status. (FDA, n.d.-b)

Which companies are challenging LITHOSTAT?

The market is unlikely to attract the same level of Paragraph IV activity as a high-revenue branded medicine. Acetohydroxamic acid addresses a narrow population, has a constrained safety profile, and does not offer the volume economics of common cardiovascular, metabolic, or anti-infective products.

A Paragraph IV challenge would be commercially rational only if the applicant can demonstrate:

• Reliable API supply
• Low-cost tablet production
• A sufficiently large reachable patient population
• Limited regulatory litigation exposure
• Reimbursement or contracting access
• A path to sustained supply despite modest unit volumes

Publicly available information does not establish a major, active Paragraph IV litigation campaign involving LITHOSTAT. A commercial entrant should verify current ANDA filings and federal litigation records before relying on a no-challenge conclusion.

What generic entry risks exist for LITHOSTAT?

Generic entry risk is primarily operational rather than patent-driven.

Regulatory risk

Acetohydroxamic acid has a narrow therapeutic use and safety warnings that may complicate labeling alignment. A generic sponsor must ensure that the proposed label remains consistent with the reference product while addressing any differences in excipients or tablet presentation.

Bioequivalence risk

A conventional immediate-release tablet may be suitable for standard bioequivalence testing. Differences in disintegration, dissolution, particle size, or excipient composition could still affect exposure. The sponsor must control:

• Assay and content uniformity
• Dissolution across relevant media
• Impurity profile
• Tablet hardness and disintegration
• Stability under accelerated and long-term conditions

Manufacturing risk

The greatest practical risk is supply continuity. A niche product may depend on a limited number of API sources, low-volume contract manufacturers, or specialized quality systems. A second-source strategy can create commercial value even without formulation innovation.

Market risk

A generic entrant may face a small market with concentrated prescribing and limited pharmacy demand. The product may require direct engagement with urologists, infectious-disease physicians, specialty pharmacies, and hospital systems.

How does LITHOSTAT compare with alternative commercial opportunities?

LITHOSTAT differs from high-volume oral drugs because formulation innovation must be tightly matched to a small, medically defined population.

Opportunity	Technical complexity	Regulatory burden	Commercial upside
Conventional generic tablet	Low to moderate	ANDA	Moderate, volume constrained
Smaller high-load tablet	Moderate	ANDA if equivalent	Moderate
Film-coated immediate-release tablet	Moderate	ANDA or 505(b)(2), depending on changes	Moderate
New strength	Moderate	ANDA supplement or 505(b)(2)	Moderate
Extended-release tablet	High	505(b)(2) likely	Higher per unit, uncertain market
Liquid formulation	Moderate to high	505(b)(2) or new application	Useful for swallowing-limited patients
Combination product with antibiotic	High	Combination-drug requirements	Potentially differentiated, clinically complex
Pediatric formulation	High	Pediatric development requirements	Limited population

A liquid or dispersible formulation could address swallowing limitations, but acetohydroxamic acid’s taste, dose volume, chemical stability, and preservative requirements would need careful evaluation. A combination product would face greater clinical and regulatory complexity because antibiotic selection depends on the infecting organism and susceptibility profile.

What licensing deals could create value?

Licensing opportunities are more likely to involve supply, formulation technology, or regional commercialization than an established blockbuster-style brand transaction.

Potential structures include:

• An API supply agreement with dual-source rights
• A U.S. commercialization license for a generic or reformulated product
• A 505(b)(2) development partnership
• A contract manufacturing agreement with technology transfer
• A regional license for a liquid or modified-release presentation
• A co-development agreement tied to a new indication or diagnostic-guided use

The most defensible transaction would link milestones to FDA acceptance, approval, validated commercial batches, and minimum supply commitments. Royalty economics should reflect the narrow indication and low expected unit volume.

What is the patent strength of the LITHOSTAT estate?

The patent estate appears weak as a current exclusivity barrier when compared with products protected by active composition, formulation, biologic, or device patents. The stronger protection opportunity lies in new, technically differentiated formulations rather than in the legacy product itself.

A new patent strategy could focus on:

• Defined excipient ratios
• Improved stability under high humidity
• Reduced impurity formation
• Specific particle-size distributions
• Improved dissolution after storage
• Reduced tablet size at equivalent dose
• Taste-masked liquid or dispersible products
• Modified-release profiles with demonstrated pharmacokinetic advantages
• Manufacturing processes that improve yield or reduce degradation

Claims should be supported by comparative data against the existing immediate-release tablet. Broad claims covering routine excipient substitution would face substantial validity risk.

What is the FDA regulatory status of LITHOSTAT?

LITHOSTAT is an FDA-approved prescription product containing acetohydroxamic acid. The labeling includes restrictions and warnings that are central to product development, particularly renal function, hematologic monitoring, and use as adjunctive therapy rather than as a replacement for infection control. (FDA, n.d.-a)

A generic immediate-release tablet would generally pursue an ANDA if it matches the reference product in active ingredient, strength, dosage form, route, and performance. A new formulation with a different release profile, route, or clinically meaningful excipient effect would likely require a 505(b)(2) strategy.

Key Takeaways

• LITHOSTAT contains acetohydroxamic acid and is used as an adjunctive urease inhibitor for infection-related urinary stones.
• The strongest near-term opportunity is a conventional generic or improved immediate-release tablet.
• Smaller tablet size, film coating, moisture control, and gastrointestinal usability are practical excipient priorities.
• Modified release could reduce dosing frequency but would create significant pharmacokinetic and regulatory risk.
• The legacy product does not appear to have a strong current formulation-patent barrier based on public FDA sources.
• Generic entry risk is driven more by market size, API supply, manufacturing economics, and regulatory execution than by active patent litigation.
• A defensible new patent would require a specific formulation or process supported by comparative technical data.
• The most credible licensing opportunities involve API supply, contract manufacturing, regional commercialization, or a 505(b)(2) reformulation.

FAQs

Can LITHOSTAT be reformulated as a smaller tablet?

Yes. A high-drug-load direct-compression design could reduce tablet size, but development must preserve dissolution, content uniformity, mechanical strength, and stability.

Is a liquid acetohydroxamic acid product commercially attractive?

It could address swallowing limitations, but taste masking, dose volume, chemical stability, preservative selection, and packaging would materially increase development complexity.

Would a new excipient combination create LITHOSTAT market exclusivity?

Not by itself. The formulation would need a patentable composition or process with evidence of an unexpected technical advantage.

Is a Paragraph IV challenge likely for LITHOSTAT?

The commercial incentive appears limited because the product serves a narrow population. Any conclusion on active or pending challenges requires review of current FDA and federal court records.

Could an extended-release LITHOSTAT product command premium pricing?

Potentially, if it reduces dosing burden or improves tolerability. The product would likely require a 505(b)(2) pathway and clinical evidence supporting the changed exposure profile.

References

1. U.S. Food and Drug Administration. (n.d.-a). LITHOSTAT (acetohydroxamic acid) tablet prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Guidance for Industry.

4. U.S. Food and Drug Administration. (2024). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA Guidance for Industry.